- Conditions
- Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
- Interventions
- AI model classification, DSOC endoscopist experts' classification
- Diagnostic Test
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 170 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 817
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV
- Interventions
- Lenacapavir long-acting, Standard of Care (SOC)
- Drug · Other
- Lead sponsor
- Kelley-Ross & Associates, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Malignant Neoplasm of Breast, Breast Cancer
- Interventions
- Genomically Directed Monotherapy, Observation/Standard Therapy
- Drug · Other
- Lead sponsor
- Bryan Schneider, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Gainesville, Florida + 24 more
- Conditions
- Lymphoma
- Interventions
- rituximab, cisplatin, cytarabine, dexamethasone, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- NCIC Clinical Trials Group
- Network
- Eligibility
- 16 Years to 65 Years
- Enrollment
- 849 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more
- Conditions
- End Stage Renal Disease
- Interventions
- there is no intervention
- Other
- Lead sponsor
- Children's National Research Institute
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 150 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Convergence Insufficiency, Divergence Insufficiency, Hypertropia
- Interventions
- Prism, Orthoptic Exercises, Eye Muscle Surgery, Botox Injection
- Device · Other · Procedure
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Cystic Fibrosis (CF)
- Interventions
- Elexacaftor / Ivacaftor / Tezacaftor, therapeutic drug monitoring
- Drug · Other
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Seattle, Washington
- Conditions
- Contact Dermatitis
- Interventions
- PDC-APB, Placebo
- Drug
- Lead sponsor
- Hapten Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Franklin, Tennessee
- Conditions
- Pneumonia, Ventilator-Associated, Pneumonia, Bacterial, Pneumonia, Hospital-Acquired
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 7,530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
- Conditions
- Adult Growth Hormone Deficiency
- Interventions
- Somapacitan
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma, Solid Tumor, Unspecified, Adult, Tumor, Solid
- Interventions
- INV-1120, Pembrolizumab
- Drug · Combination Product
- Lead sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 3
- States / cities
- Lafayette, Indiana • San Antonio, Texas
- Conditions
- Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Electronic Health Record Review
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Failure, Chronic, Renal Failure Chronic, Hemodialysis
- Interventions
- Bioimpedance spectroscopy (BIS) measurement, SOZO device
- Device
- Lead sponsor
- ImpediMed Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- San Diego, California
- Conditions
- Fibromyalgia
- Interventions
- amino acid-based blend
- Dietary Supplement
- Lead sponsor
- Pekarovics, Susan, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Older Adults, Physical Deconditioning
- Interventions
- Progressive Multi-Component (PMC), Enhanced Usual Care (EUC)
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Breast Cancer
- Interventions
- Observational study no intervention
- Other
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more
- Conditions
- Lymphedema, Breast Cancer
- Interventions
- Surgical Intervention, Conservative Complex Physical Decongestion Therapy
- Procedure
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Epilepsy
- Interventions
- Observational only, Psychological and Behavioral interaction with a seizure forecasting mobile app, Seizure Alerting and Prediction System
- Device · Behavioral · Combination Product
- Lead sponsor
- Epitel, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
- Interventions
- CDX-1127
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
- Conditions
- Deep Venous Thrombosis, Post-thrombotic Syndrome
- Interventions
- PET/CT
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Body Image, Eating Disorder Symptom, Weight Bias
- Interventions
- EVERYbody Project-Connect, Self-Help Workbook
- Behavioral
- Lead sponsor
- Western Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Bellingham, Washington
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Interventions
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Device
- Lead sponsor
- THYROSCOPE INC.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Venous Leg Ulcer (VLU)
- Interventions
- Omeza OCM™ Wound Matrix, Routine Care
- Device · Procedure
- Lead sponsor
- Omeza, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Lake Success, New York